Keywords
CCHF; hemorrhagic fever, ribavirin, convalescent blood plasma, treatment
Abstract
We initiated the retrospective study of 81 patients with Crimean-Congo hemorrhagic fever in the Republic of Uzbekistan for a period from June 2013th to June 2018th. This article presents the results of a comparison of mortality depending on etiological antiviral treatment. The comparison groups included four types of therapy: a) patients who received ribavirin according to WHO standards; b) those who received ribavirin+convalescent blood plasma; c) patients who received only convalescent blood plasma; and d) only supportive treatment without the use of ribavirin and convalescent blood plasma. Considering the limitations of observational studies, we concluded that the type of therapy did not play a role in reducing CCHF mortality.